filtered normal pooled plasma cryocheck (Precision Biologic Inc)
90
Structured Review
Precision Biologic Inc
filtered normal pooled plasma cryocheck
Filtered Normal Pooled Plasma Cryocheck, supplied by Precision Biologic Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/filtered+normal+pooled+plasma+cryocheck/filtered+normal+pooled+plasma+cryocheck/10__1097_slash_mbc__0b013e32835e63b7-100-35-38
Average 90 stars, based on 1 article reviews
Filtered Normal Pooled Plasma Cryocheck, supplied by Precision Biologic Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/filtered+normal+pooled+plasma+cryocheck/filtered+normal+pooled+plasma+cryocheck/10__1097_slash_mbc__0b013e32835e63b7-100-35-38
Average 90 stars, based on 1 article reviews
filtered normal pooled plasma cryocheck - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Suspension:Article Title: Blood clotting activation analysis for preoperative differentiation of benign versus malignant ovarian masses Article Snippet: Preoperative evaluation of patients presenting with ovarian masses is challenging, partly due to shortcomings with the commonly used marker, CA-125.. Ovarian cancer is associated with systemic coagulation activation.. Measurement of D-dimer, serum tissue factor (TF), and the coagulation process as a whole are considered candidates for improving discrimination between benign and malignant ovarian masses. Clinical Proteomics:Article Title: Blood clotting activation analysis for preoperative differentiation of benign versus malignant ovarian masses Article Snippet: Preoperative evaluation of patients presenting with ovarian masses is challenging, partly due to shortcomings with the commonly used marker, CA-125.. Ovarian cancer is associated with systemic coagulation activation.. Measurement of D-dimer, serum tissue factor (TF), and the coagulation process as a whole are considered candidates for improving discrimination between benign and malignant ovarian masses. |